Target intelligence / Profile preview

Transglutaminase enzyme (TG (commonly used); TG2 (for tissue transglutaminase, a prominent member of the family))

Target
TG (commonly used); TG2 (for tissue transglutaminase, a prominent member of the family)
Molecular classification
Enzyme, Transferase (specifically, protein-glutamine γ-glutamyltransferase), Multifunctional protein (some, e.g. TG2, have additional GTPase activity), Member of the transglutaminase family
01

Overview

Transglutaminases are a family of enzymes that catalyze post-translational modification of proteins by forming covalent cross-links between lysine and glutamine residues, creating resilient isopeptide bonds. These enzymes are widely distributed in nature, with at least eight members encoded in the human genome. Their activities are involved in diverse biological functions including stabilization of the extracellular matrix, regulation of cell adhesion and motility, wound healing, apoptosis, and blood clotting. Transglutaminases—especially tissue transglutaminase (TG2)—are implicated in diseases such as cancer, neurodegeneration, and autoimmunity (notably celiac disease, as TG2 is a major autoantigen). In food technology, microbial transglutaminase is used for protein cross-linking, known as "meat glue." Therapeutic targeting of transglutaminase enzymatic activity is an active area of research for autoimmune and fibrotic diseases, but is challenged by their multifunctional roles and widespread biological importance[1][2][3][4][5][6][9][10].

Other names
TGTissue transglutaminase (for TG2)Protein-glutamine-γ-glutamyltransferaseMeat glue (in food industry)
02

Mechanism of action

Inhibition of cross-linking enzymatic activity (blocking isopeptide bond formation) Inhibition of post-translational modification or deamidation of glutamine residues Blocking protein-protein cross-linking may reduce tissue fibrosis or autoantigen generation

03

Biological functions

Protein cross-linking (formation of isopeptide bonds between glutamine and lysine residues)Post-translational modification of proteinsStabilization of extracellular matrixRegulation of cell adhesion, motility, and differentiationSignal transduction (TG2 acts as a G-protein and can hydrolyze GTP)Apoptosis (cell death regulation)Blood clotting (e.g. Factor XIII)Skin barrier and bone formationCell fate regulation
04

Disease associations

CancerNeurodegenerative diseasesAutoimmune diseases (e.g. celiac disease)Progressive tissue fibrosisSkin disordersChronic inflammationBleeding disorders (genetic deficiencies)
05

Safety considerations

Potential for autoimmune responses — TG2 is a known autoantigen in celiac diseaseOveractivity can contribute to tissue fibrosis, neurodegeneration, or cancerLoss-of-function variants can cause bleeding (factor XIII deficiency) or skin barrier defectsManipulation in food industry may raise allergy or processing safety concerns
06

Interacting drugs

There are experimental transglutaminase inhibitors under development for celiac disease and other autoimmune conditions; commercial transglutaminase inhibitors are not widely available or clinically approved for most uses. Representative compounds include cystamine and novel small-molecule inhibitors (mostly experimental). No standard, clinically used drugs directly target TGs outside specialized research/industry.
07

Biomarkers

Anti-transglutaminase antibodies (especially anti-TG2) are biomarkers for celiac disease diagnosis and monitoringTG activity levels may correlate with disease states (e.g. fibrosis, cancer, autoimmune disorders)TG expression and activity in tissues may provide prognostic or diagnostic information

Beyond the preview

Go deeper on Transglutaminase enzyme (TG (commonly used); TG2 (for tissue transglutaminase, a prominent member of the family)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transglutaminase enzyme (TG (commonly used); TG2 (for tissue transglutaminase, a prominent member of the family)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call